Bosutinib in combination with the aromatase inhibitor letrozole: A phase II trial in postmenopausalwomen evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Oncologist

Volumn 19, Issue 4, 2014, Pages 348-349

  Moy, Beverly ^a   Neven, Patrick ^b   Lebrun, Fabienne ^c   Bellet, Meritxell ^d   Xu, Binghe ^e   Sarosiek, Tomasz ^f   Chow, Louis ^g   Goss, Paul ^a   Zacharchuk, Charles ^h   Leip, Eric ^h   Turnbull, Kathleen ^h   Bardy Bouxin, Nathalie ^h   Duvillié, Ladan ^h   Láng, István ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e CANCER HOSPITAL   (China)

^f NZOZ Centrum Medyczne   (Poland)

^g UNIMED Medical Institute   (Hong Kong)

^h PFIZER INC   (United States)

ⁱ NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; LETROZOLE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; NITRILE; PROGESTERONE RECEPTOR; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; VOMITING; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NITRILES; POSTMENOPAUSE; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 84898449429     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0021     Document Type: Article

References (0)